Open AccessKompleksnaya terapiya pri aterogennoydislipidemii i nealkogol'noy zhirovoybolezni pecheni
Author(s) -
Е. А. Черкашова,
L. A. Zvenigorodskaya,
Natal'ya Gennad'evna Samsonova,
Nilova Tamara,
Svetlana Yur'evna Sil'vestrova,
Sergey G. Khomeriki
Publication year - 2011
Publication title -
cardiosomatika
Language(s) - English
Resource type - Journals
eISSN - 2658-5707
pISSN - 2221-7185
DOI - 10.26442/cs44962
Subject(s) - dyslipidemia , medicine , fatty liver , probiotic , gastroenterology , metabolic syndrome , nitric oxide , pathogenesis , disease , cholesterol , biology , obesity , bacteria , genetics
Summary. Non-alcoholic fatty liver disease (NAFLD) is one of the major components of the metabolic syndrome.NAFLD is now recognized as one of the major cardiovascular risk factors since cholesterol synthesis takes place inthe liver. In this connection, to choose hypolipidemic therapy that has well-known hepatotoxic effects is an intricateproblem. Of great importance in the pathogenesis of NAFLD is the impaired colonic microflora and hence elevatedlevels of microbial waste products (short-chain fatty acids, endotoxin, nitric oxide), which should be alsokept in mind when treating atherogenic dyslipidemia. Statin + probiotic combination therapy used in patients withNAFLD and atherogenic dyslipidemia is more effective than monotherapy in reducing the levels of cholesterol andintestinal microflora metabolism products.